These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2007 related items for PubMed ID: 28157070

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
    Zhang ZH, Liu QX, Zhang W, Ma JQ, Wang JH, Luo JJ, Liu LX, Yan ZP.
    World J Gastroenterol; 2017 Nov 21; 23(43):7735-7745. PubMed ID: 29209114
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
    Ni JY, Kong J, Sun HL, Chen YT, Luo JH, Wang WD, Chen D, Jiang XY, Xu LF.
    Acad Radiol; 2018 Apr 21; 25(4):423-429. PubMed ID: 29198946
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Li L, Zhao W, Wang M, Hu J, Wang E, Zhao Y, Liu L.
    BMC Gastroenterol; 2018 Sep 04; 18(1):138. PubMed ID: 30180810
    [Abstract] [Full Text] [Related]

  • 12. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX, Gan YH, Ge NL, Chen Y, Ma H, Wang Y, Zhang BH, Wang YH, Ye SL, Luo JF, Ren ZG.
    J Gastroenterol Hepatol; 2016 Feb 04; 31(2):442-9. PubMed ID: 26259976
    [Abstract] [Full Text] [Related]

  • 13. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
    Cho JY, Paik YH, Park HC, Yu JI, Sohn W, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.
    Liver Int; 2014 May 04; 34(5):795-801. PubMed ID: 24350564
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.
    Pecorelli A, Lenzi B, Gramenzi A, Garuti F, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Morisco F, Gasbarrini A, Baroni GS, Foschi FG, Biasini E, Masotto A, Virdone R, Bernardi M, Trevisani F, Italian LiverCancer (ITA.LI.CA) group.
    Liver Int; 2017 Mar 04; 37(3):423-433. PubMed ID: 27566596
    [Abstract] [Full Text] [Related]

  • 16. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
    Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, Shin YM, Kim KM, Lim YS, Lee HC.
    Radiology; 2013 Nov 04; 269(2):603-11. PubMed ID: 23864102
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.
    Zhao Y, Wang WJ, Guan S, Li HL, Xu RC, Wu JB, Liu JS, Li HP, Bai W, Yin ZX, Fan DM, Zhang ZL, Han GH.
    Ann Oncol; 2013 Jul 04; 24(7):1786-1792. PubMed ID: 23508822
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
    Liu F, Meng Z, Shao G, Wang J, Wang Z, Yang J, Yip CS, He D.
    Mol Biol Rep; 2017 Feb 04; 44(1):149-158. PubMed ID: 27981445
    [Abstract] [Full Text] [Related]

  • 20. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM, Jang BK, Lee YJ, Choi WY, Choi SM, Chung WJ, Hwang JS, Kang KJ, Kim YH, Chauhan AK, Park SY, Tak WY, Kweon YO, Kim BS, Lee CH.
    Clin Mol Hepatol; 2016 Mar 04; 22(1):160-7. PubMed ID: 27044767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 101.